All In Biotech

Drug Trial Radar · NCT07244263

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess Efficacy and Safety of Zasocitinib in Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

91

Actual

Start

Jan 26, 2026

Primary completion

Feb 5, 2027

Study completion Feb 22, 2028

Sponsor

Lead sponsor
TakedaTakeda (TAK)
Sponsor type
Industry
First posted
Nov 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hidradenitis Suppurativa (HS) is a skin condition that causes deep, painful bumps on the skin. These bumps usually appear in an area where the skin rubs together. They start as small bumps but may become swollen and red over time. If they fill with pus, these lumps are called abscesses; these can also burst. Over time, the area can get scars and tunnels on or under the skin. Recent studies suggest that the condition may start when hair follicles become damaged and blocked. This impacts the skin and may activate the body's germ-fighting (immune) system. This allows bacteria to grow on the skin which worsens the condition and can cause abscesses. The main aims of this study are to learn how safe zasocitinib is, how well it works and how well adults with HS tolerate it compared with a placebo. The participants will receive the study treatment (either zasocitinib or placebo) for up to 4 months (16 weeks). The placebo looks like the zasocitinib capsule but does not have any medicine in it. After the first 4 months, all participants (also those who initially received placebo) will then receive zasocitinib for up to 8 months (36 weeks). During the study, participants will visit their study clinic 12 times.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • Zasocitinib (Dose A)Drug

    Zasocitinib.

  • PlaceboOther

    Placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants who Achieve 75 Percent (%) Reduction in Hidradenitis Suppurativa Clinical Response (HiSCR75)Time frame: At Week 16

Locations

45 sites in 8 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Scottsdale, Arizona

  • Johnson Dermatology

    Fort Smith, Arkansas

  • First OC Dermatology Research

    Fountain Valley, California

  • Direct Helpers Research Center

    Hialeah, Florida

  • Advanced Clinical Research Institute

    Tampa, Florida

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Wayne State University

    Detroit, Michigan

  • Hamzavi Dermatology

    Fort Gratiot, Michigan

  • StracSkin, PLLC

    Greenland, New Hampshire

  • Northwell Health Physician Partners

    Lake Success, New York

  • Mount Sinai Doctors

    New York, New York

  • Apex Clinical Research Center, LLC.

    Mayfield Heights, Ohio

  • ODRC Enterprises, LLC dba Oregon Dermatology and Research Center

    Portland, Oregon

  • Arlington Research Center, Inc.

    Arlington, Texas

  • Texas Dermatology Research Center

    Dallas, Texas

  • Skin & Cancer Foundation - The Skin Hospital

    Darlinghurst, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Skin Health Institute Inc.

    Carlton, Victoria, Australia

  • Sinclair Dermatology

    Melbourne, Victoria, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • Beacon Dermatology

    Calgary, Alberta, Canada

  • Brunswick Dermatology Center

    Fredericton, New Brunswick, Canada

  • CCA Medical Research

    Ajax, Ontario, Canada

  • SimcoDerm Medical and Surgical Dermatology Centre

    Barrie, Ontario, Canada

  • SKiN Centre for Dermatology

    Peterborough, Ontario, Canada

  • Innovaderm Research Inc.

    Montreal, Quebec, Canada

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, China

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

  • Southern Medical Universtiy - Dermatology Hospital (SMUDH) (Guangdong Provincial Dermatology Hospital)

    Guangzhou, Guangdong, China

  • Union Hospital Tongji Medical College of Huazhong University of Science and Technology (HUST)

    Wuhan, Hubei, China

  • Huashan Hospital, Fudan University, Shanghai

    Shanghai, Shanghai Municipality, China

  • CHU de Rouen

    Rouen, France

  • CHU NICE

    Nice, Alpes Maritimes, France

  • Hopital Edouard Herriot

    Lyon, Rhone, France

  • Centre Hospitalier Le Mans

    Le Mans, Sarthe, France

  • Charite Dermatology

    Berlin, Germany

  • Fachklinik Bad Bentheim

    Bad Bentheim, Lower Saxony, Germany

  • Katholisches Klinikum Bochum gGmB

    Bochum, Northrhine Westfalia, Germany

  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz - Hautklinik und Poliklinik - Clinical Research Center (CRC)

    Mainz, Rhineland-Palatine, Germany

  • ErasmusMC

    Rotterdam, South Holland, Netherlands

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.